Laboratoire Innotech International S.A.S.

What Laboratoire Innotech International S.A.S. does

Laboratoire Innotech International S.A.S. is the international distribution arm of the INNOTHERA Group, a French family-owned pharmaceutical and medical device company founded in 1913 (originally as Laboratoires Chantereau). The company designs, develops, manufactures, and distributes medications, medical compression textiles, medical devices, and hygiene/protection products addressing ten therapeutic areas including venous insufficiency, gynecological infections, contraception, iron deficiency, intestinal disorders, respiratory conditions, and hospital infection control. Its portfolio encompasses 16+ medications (Phlebodia, Polygynax, Pharmatex, Diovenor, Tot'Hema, Fluditec, etc.), 5+ compression device brands (Varisma, Legger, Actys, Smartleg, Tubulcus), hygiene products under the Cleanis subsidiary (CareBag, Aqua, GelMax), and diagnostic devices (BB Test, Innotex). The group holds 1,000+ Marketing Authorizations worldwide and operates 4 French manufacturing plants (Arcueil HQ, Chouzy-sur-Cisse, Nomexy, plus Gibaud sites), mastering 15 different pharmaceutical galenic forms.

The business model is primarily transactional (one-time sale of products) supplemented by international distribution margins. Go-to-market combines a direct field sales force of 80 commercial representatives across seven French regions targeting pharmacies, hospitals, and healthcare professionals, with international distribution managed through the INNOTECH International subsidiary reaching 100+ countries via own offices (Moscow), subsidiaries (INNOTHERA Baltics, Cleanis Inc.), specialized agents, and 130+ exclusive representatives across 30 African countries. The company also pursues co-development partnerships for connected medical textiles (BioSerenity, 2016) and AI-driven health applications (TheraPanacea, 2019). Customer segments are primarily B2B2C via pharmacy intermediaries, with additional direct sales to hospitals and clinics. Pricing is not publicly disclosed but operates through commercial negotiations via the field sales force and agent network.

Consolidated INNOTHERA group revenue reached €241 million in 2020 (including the Gibaud acquisition), with Laboratoire Innotech International specifically contributing €114 million. Exports represent more than 70% of global revenue. The company employs 1,180 people worldwide, of which 747 are based in France, with the balance spread across Russia/CIS, Africa, and other international operations. R&D investment stands at 7.1% of revenue (2021), supporting both pharmaceutical innovation and connected textile development through the Biophysics Research Laboratory at Arcueil and the Department Recherche Analytique et Galénique at Chouzy-sur-Cisse.

Name

Laboratoire Innotech International S.A.S.

Legal name

INNOTHERA S.A.

Website

https://innothera.fr

Company type

Private

Founded year

1913

Operating status

Operating

Headcount range

11–50 employees

Short description

Laboratoire Innotech International S.A.S. is the international distribution subsidiary of French family-owned INNOTHERA Group, distributing pharmaceutical medications, medical compression textiles, hygiene products, and medical devices to pharmacies, hospitals, and healthcare professionals across 100+ countries.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

akta.pro secondary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

Keywords

• Pharmaceutical manufacturing
• Medical compression devices
• Venous disease treatments
• Women's health medication
• Hospital hygiene products

Headquarters

HQ city

Arcueil

HQ country

France

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Medications/Pharmaceuticals: Development and production of medications for treatment of daily pathologies including venous insufficiency, gynecological infections, respiratory conditions, iron deficiency, intestinal transit disorders, and contraception. The company produces over 20 medications and holds 1,000+ Marketing Authorizations worldwide.
2. Medical Compression Textiles: Production and sale of medical compression devices including compression stockings, tights, and socks under brands such as Varisma, Legger, Actys, Smartleg, and Tubulcus for venous disease treatment.
3. Medical Devices: BB Test (pregnancy test), Innotex (condom), and other diagnostic and medical devices.
4. Hygiene and Protection Products: CareBag (absorbent hygiene bags for bodily fluid collection), Aqua (no-rinse washing products), and GelMax (super-absorbent products) for hospital hygiene and infection prevention, commercialized through Cleanis subsidiary.
5. Export/Distribution: International distribution of products through INNOTECH International subsidiary, including export of finished products, semi-finished bulk products, and local packaging in over 100 countries.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

Laboratoire Innotech International S.A.S. develops, manufactures, and distributes pharmaceutical medications, medical compression textiles, medical devices, and hygiene products targeting daily pathologies. Its portfolio spans prescription and OTC drugs (phlebology, gynecology, ENT, parasitology, dermatology, pediatrics), elastic compression stockings and ortheses, and hospital hygiene solutions, sold through pharmacies, hospitals, and healthcare professionals in more than 100 countries.

Product overview

Laboratoire Innotech International S.A.S. is the international subsidiary of INNOTHERA, distributing a diversified portfolio of health products across more than 100 countries. The product portfolio encompasses 16 medications including PHLEBODIA® (vasculoprotector), POLYGYNAX® (gynecological anti-infective), PHARMATEX® (contraceptive), and TOT'HEMA® (antianemic); 5 medical compression devices including SMARTLEG® (connected compression textile), LEGGER® (men's and women's compression stockings), ACTYS®, and TUBULCUS®; hygiene products including CAREBAG® (infection control), AQUA® (patient hygiene), and GELMAX® (absorbent pad); plus diagnostic devices like BB TEST® (pregnancy test) and dietary supplements like INOCLIM®.

Differentiator

Problem solved

Functional benefit

Brands

• PHLEBODIA: Medication for venous insufficiency
• POLYGYNAX
• DERMOBACTER
• DIOVENOR
• IDEOS
• SMARTLEG
• VARISMA
• LEGGER
• ACTYS
• TUBULCUS
• CAREBAG
• AQUA
• GELMAX

Products and services

• Phlebodia (diosmin/venous insufficiency medication)

Quantifiable outcome

• 30%+ patient non-adherence to compression treatment after 15 days identified as key challenge, driving VIP Adhesion patient education program
• +2 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• TheraPanaceacoreStrategic or Co-development Partner · 1 January 2019Innovation partnership with AI start-up TheraPanacea (from Inria and CentraleSupélec research laboratories) to apply artificial intelligence technologies to treatment and prevention of daily pathologies. INNOTHERA invested 3.5 million euros through THERINVEST family fund. Partnership aims to develop data collection, processing, and exploitation procedures, as well as new industrial and technological techniques for INNOTHERA's business domains.
• BioSerenitycoreStrategic or Co-development Partner · 30 June 2016R&D and industrial partnership signed June 30, 2016, where INNOTHERA also took a participation in BioSerenity's capital. Partnership focuses on developing Connected Medical Textiles in angiology and gynecology-obstetrics, as well as industrialization of connected textile devices in cardiology, neurology, and sleep disorders at the Nomexy factory. Some projects received FUI 20 funding and Bpifrance support.
• CleaniscoreStrategic or Co-development PartnerSubsidiary specializing in hospital hygiene and infection prevention products. INNOTHERA became sole shareholder in May 2016. Products include CareBag (absorbent hygiene bags awarded gold medal at Lépine competition), Aqua (no-rinse washing products), and GelMax (super-absorbent products). Cleanis exports to USA, Japan, and other markets with about 30 collaborators based in Paris.
• GibaudcoreStrategic or Co-development PartnerAcquisition completed creating a French champion in medical devices. Gibaud brings 130 years of expertise in orthopedic textiles (1890), compression venous elastic products, and podology. With 37 patents since 2001 and 360 employees at Saint-Etienne and Trévoux sites. Combined entity achieves 250M€ revenue with 110M€ in medical devices.
• Pro FranceminorGTM or Marketing PartnerAssociation promoting the Origine France Garantie label. INNOTHERA partnered as official sponsor of the 1st and 2nd Assises du Produire en France (2015, 2016) events, reaffirming commitment to French manufacturing and the Made in France label.
• Pro FranceminorGTM or Marketing PartnerAssociation promoting the Origine France Garantie label. INNOTHERA partnered as official sponsor of the 1st and 2nd Assises du Produire en France (2015, 2016) events, reaffirming commitment to French manufacturing and the Made in France label.
• OVHminorOthersWeb hosting provider for INNOTHERA's websites. OVH is a French cloud computing company hosting the company's digital infrastructure.

Scale indicators11 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Thuasne: French family-owned medical device company specializing in compression therapy, orthopedics, and medical textiles. Direct peer given nearly identical product categories (compression stockings, orthopedic devices), French manufacturing base, family ownership structure, and comparable mid-cap scale in medical devices.
• Sigvaris: Swiss-headquartered global leader in medical compression therapy (stockings, socks, tights). Direct peer given virtually identical product portfolio in elastic venous compression, overlapping Class 1-3 compression products, and shared focus on chronic venous disease treatment across global markets.
• Urgo: French family-owned medical device and pharmaceutical company specializing in wound care, compression therapy, and OTC products. Direct peer given parallel French manufacturing base, family ownership model, mid-cap scale, and dual presence in medical devices and consumer healthcare categories.
• Pierre Fabre: French private pharmaceutical and dermo-cosmetic group with €2.5B+ revenue. Direct peer given parallel structure as French family/foundation-owned pharma company with branded pharmaceutical manufacturing, significant women's health portfolio (contraception, gynecology), and 100% French production base.
• Servier: French private pharmaceutical group with €4.7B+ revenue, independently owned by a non-profit foundation. Direct peer given shared profile as French branded pharma manufacturer with cardiovascular focus, international presence in 100+ countries, and independent ownership structure enabling long-term R&D investment cycles.
• medi: German medical device company with strong compression therapy portfolio (mediven, duomed brands) plus orthopedic and phlebology products. Direct peer in medical compression textiles with similar class-based product segmentation and global distribution presence spanning 100+ countries.

Broad incumbents

• BSN Medical (Essity): Now part of Swedish hygiene giant Essity, BSN Medical offers compression therapy (Jobst brand), wound care, and orthopedics. Broad incumbent with direct overlap in medical compression stockings and orthopedic products, serving similar patient populations in venous disease and post-surgical recovery.
• Hartmann: German-headquartered, family-controlled medical and hygiene products company with strong positions in wound care, incontinence management, and infection control. Broad incumbent with overlapping hospital hygiene portfolio (similar to Cleanis products) and partial overlap in compression therapy.

Emerging players

• Coloplast: Danish medical device company focused on ostomy, continence, wound care, and skin care. Emerging player with partial overlap in hospital hygiene and infection control products similar to Cleanis, though primary focus differs (ostomy and continence vs. compression and pharma).

Others

• Össur: Icelandic global leader in non-invasive orthopedics (prosthetics, bracing, compression therapy). Connected to INNOTHERA as the prior owner of Gibaud (acquired by INNOTHERA in 2020). Relevant comparator for orthopedic and compression therapy market dynamics, though now a divested counterparty rather than direct competitor.

Market position

Strengths5 records

Weaknesses5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/laboratoire-innotech-international-s.a.s.

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Laboratoire Innotech International S.A.S.